Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial Of The Impact Of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction In Endometrial Cancer

NCT05646316 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT05646316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05646316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial Of The Impact Of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction In Endometrial Cancer
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
December 7, 2022
Completion date
October 31, 2026
Enrollment
428 (estimated)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

stage i uterine corpus carcinoma or carcinosarcoma ajcc v8